First Affiliated Hospital Xi'an Jiaotong University
Phase
Not applicable
Started
2024-06-27
Last updated
2026-07-21
Condition(s) studied
Ischemic Preconditioning
Investigational drug(s) / intervention(s)
Remote ischaemic preconditioning
Remote ischaemic preconditioning: The participants rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training for participants in group A will be performed once daily, while for participants in group B the training will be performed twice daily. And heart rate and blood pressure before and after each training will be recorded for 7 days.
Study summary
The aim of this study is to investigate the effects of remote ischaemic preconditioning on the peripheral blood characteristics of healthy adults and to explore the possible mechanisms for improving ischaemia/reperfusion injury and its protective effects on the cardiovascular system.
Eligibility
Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Aged 18 to 45 years;
* Be in good health;
* Consent to participate in the clinical trial and sign the informed consent form.
Exclusion Criteria:
* Abnormal results in biochemical checks and physiological indicators.
* Cardiovascular and cerebrovascular diseases: hypertension, coronary heart disease, congenital heart disease, cerebrovascular alterations, etc.
* Endocrine diseases: diabetes, thyroid disorders, etc.
* Hematologic diseases: anemia, paroxysmal hemoglobinuria, primary thrombocytosis, etc.
* Infectious diseases: hepatitis B, hepatitis C, syphilis, etc.
* Cancer.
* Neurological and psychiatric disorders.
* Vascular diseases: peripheral vascular disease, Raynaud's syndrome, thromboembolic diseases.
* Major trauma or surgery within the last six months.
* Pregnant or breastfeeding women.
* Upper limbs unsuitable for compression treatment: history of upper limb surgery, presence of tissue damage and limb deformity, and concomitant hemorrhagic diseases.
* Recent circumstances that may affect results: blood donors within the last month, any medication taken within the last month, fever within the last week, women within their menstrual cycle or within 7 days before the start of menstruation.
* Patients who refuse to sign the informed consent form for participation in this study.
Primary outcome measure(s)
Changes in the expression levels of cardiovascular disease-related molecules — Baseline (before training), the end of the training day (7th day from the start of training), 7th day after the end of training Changes in the expression levels of cardiovascular disease-related molecules between participants in group A (intermediate RIPC training, once a day) or B (intense RIPC training, twice a day)
Trial sites (1)
Facility
City
Region
Status
First Affiliated Hospital of Xian Jiantong University
Xi'an
Shaanxi
Recruiting
More First Affiliated Hospital Xi'an Jiaotong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.